Enigmol: A novel sphingolipid analogue with anticancer activity against cancer cell lines and in vivo models for intestinal and prostate cancer

Molecular Cancer Therapeutics

Volumn 10, Issue 4, 2011, Pages 648-657

  Symolon, Holly ^a,b   Bushnev, Anatoliy ^b   Peng, Qiong ^a   Ramaraju, Harsha ^a,c   Mays, Suzanne G ^c   Allegood, Jeremy C ^a   Pruett, Sarah T ^b   Sullards, M Cameron ^a   Dillehay, Dirck L ^c   Liotta, Dennis C ^b   Merrill Jr , Alfred H ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; ENIGMOL; GENE PRODUCT; SPHINGOLIPID; SPHINGOSINE KINASE; UNCLASSIFIED DRUG;

ACETYLATION; ACYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GENE; CANCER CELL CULTURE; CARCINOGENESIS; COLON CANCER; COLON POLYPOSIS; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG UPTAKE; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INTESTINE CANCER; INTESTINE TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR XENOGRAFT; XENOGRAFT;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL NUCLEUS; HT29 CELLS; HUMANS; INTESTINAL NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR STRUCTURE; MUTATION; PROSTATIC NEOPLASMS; SPHINGOLIPIDS; SPHINGOSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955787364     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0754     Document Type: Article

References (51)

1. Saddoughi SA, Song P, Ogretmen B. Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 2008;49:413-40.
2. Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008;60:181-95.
3. Dindo D, Dahm F, Szulc Z, Bielawska A, Obeid LM, Hannun YA, et al. Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells. Mol Cancer Ther 2006;5:1520-9. (Pubitemid 44070489)
4. Heakal Y, Kester M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells. Mol Cancer Res 2009;7:724-34.
5. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604-16. (Pubitemid 39025055)
6. Borek C, Ong A, Stevens VL, Wang E, Merrill AH Jr. Long-chain (sphingoid) bases inhibit multistage carcinogenesis in mouse C3H/10T1/2 cells treated with radiation and phorbol 12-myristate 13-acetate. Proc Natl Acad Sci U S A 1991;88:1953-7.
7. Borek C, Merrill AH Jr. Sphingolipids inhibit multistage carcinogenesis and protein kinase C. Basic Life Sci 1993;61:367-71.
8. Stevens VL, Owens NE, Winton EF, Kinkade JM Jr, Merrill AH Jr. Modulation of retinoic acid-induced differentiation of human leukemia (HL-60) cells by serum factors and sphinganine. Cancer Res 1990;50:222-6. (Pubitemid 20041217)
9. Jarvis WD, Fornari FA, Traylor RS, Martin HA, Kramer LB, Erukulla RK, et al. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J Biol Chem 1996;271:8275-84. (Pubitemid 26108660)
10. Auzenne E, Leroux ME, Hu M, Pollock RE, Feig B, Klostergaard J. Cytotoxic effects of sphingolipids as single or multi-modality agents on human melanoma and soft tissue sarcoma in vitro. Melanoma Res 1998;8:227-39. (Pubitemid 28313760)
11. Schmelz EM, Dombrink-Kurtzman MA, Roberts PC, Kozutsumi Y, Kawasaki T, Merrill AH Jr. Induction of apoptosis by fumonisin B1 in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. Toxicol Appl Pharmacol 1998;148:252-60.
12. Desai K, Sullards MC, Allegood J, Wang E, Schmelz EM, Hartl M, et al. Fumonisins and fumonisin analogs as inhibitors of ceramide synthase and inducers of apoptosis. Biochim Biophys Acta 2002;1585:188-92. (Pubitemid 36096857)
13. Sweeney EA, Sakakura C, Shirahama T, Masamune A, Ohta H, Hakomori S, et al. Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer 1996;66:358-66. (Pubitemid 26166198)
14. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, et al. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 2006;1758:1864-84. (Pubitemid 44879367)
15. Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, et al. Safingol (l-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy 2009;5:184-93.
16. Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill AH Jr. Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr 1994;124:702-12. (Pubitemid 24157291)
17. Duan RD, Nilsson A. Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development. Prog Lipid Res 2009;48:62-72.
18. Schmelz EM, Dillehay DL, Webb SK, Reiter A, Adams J, Merrill AH Jr. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 1996;56:4936-41.
19. Symolon H, Schmelz EM, Dillehay DL, Merrill AH Jr. Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2- dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. J Nutr 2004;134:1157-61. (Pubitemid 38619956)
20. Schmelz EM, Roberts PC, Kustin EM, Lemonnier LA, Sullards MC, Dillehay DL, et al. Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 2001;61:6723-9. (Pubitemid 32896494)
21. Simon KW, Roberts PC, Vespremi MJ, Manchen S, Schmelz EM. Regulation of beta-catenin and connexin-43 expression: targets for sphingolipids in colon cancer prevention. Mol Nutr Food Res 2009;53:332-40.
22. Bergelin N, Blom T, Heikkila J, Lof C, Alam C, Balthasar S, et al. Sphingosine kinase as an oncogene: autocrine sphingosine 1-phosphate modulates ML-1 thyroid carcinoma cell migration by a mechanism dependent on protein kinase C-alpha and ERK1/2. Endocrinology 2009;150:2055-63.
23. Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K, et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 2006;26:7211-23. (Pubitemid 44477697)
24. Humpf HU, Schmelz EM, Meredith FI, Vesper H, Vales TR, Wang E, et al. Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor. J Biol Chem 1998;273:19060-4. (Pubitemid 28366299)
25. Bushnev AS, Baillie MT, Holt JJ, Menaldino DS, Merrill AH Jr, Liotta DC. An efficient asymmetric synthesis of Enigmols (1-deoxy-5-hydroxysphingoid bases), an important class of bioactive lipid modulators. ARKIVOC 2010; 2010:263-77.
26. Hannun YA, Merrill AH Jr, Bell RM. Use of sphingosine as inhibitor of protein kinase C. Methods Enzymol 1991;201:316-28.
27. Merrill AH Jr, Sullards MC, Allegood JC, Kelly S, Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005;36:207-24.
28. Dillehay DL, Webb SK, Schmelz EM, Merrill AH Jr. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr 1994;124:615-20. (Pubitemid 24157280)
29. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23. (Pubitemid 44450469)
30. Pewzner-Jung Y, Ben-Dor S, Futerman AH. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J Biol Chem 2006;281:25001-5. (Pubitemid 44401887)
31. Morales PR, Dillehay DL, Moody SJ, Pallas DC, Pruett S, Allgood JC, et al. Safingol toxicology after oral administration to TRAMP mice: demonstration of safingol uptake and metabolism by Nacylation and N-methylation. Drug Chem Toxicol 2007;30:197-216.
32. Sullards MC, Merrill AH Jr. Analysis of sphingosine 1-phosphate, ceramides, and other bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Sci STKE 2001;2001:PL1.
33. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells. J Biol Chem 2006;281:17751-7. (Pubitemid 44035574)
34. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 2010;35:161-8.
35. Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev 2009;35:1-8.
36. Smith ER, Merrill AH, Obeid LM, Hannun YA. Effects of sphingosine and other sphingolipids on protein kinase C. Methods Enzymol 2000;312:361-73.
37. Garnier-Amblard EC, Mays SG, Arrendale RF, Baillie MT, Bushnev AS, Culver DG, et al. A Novel Synthesis and Biological Evaluation of Enigmols (2-Amino-3,5-Dihydroxyoctadecanes) as Therapeutic Agents for Treating Prostate Cancer. ACS Med Chem Letters 2011 (in press).
38. Seiferlein M, Humpf HU, Voss KA, Sullards MC, Allegood JC, Wang E, et al. Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro and in vivo by ceramide synthase to form cytotoxic N-acyl-metabolites. Mol Nutr Food Res 2007;51:1120-30. (Pubitemid 47522806)
39. Ling LU, Lin H, Tan KB, Chiu GN. The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol 2009;35:1463-71.
40. 2+-exchanger in HCT116 human colon cancer cells. Arch Pharm Res 2008;31:54-9.
41. Padron JM, Peters GJ. Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures. Invest New Drugs 2006;24:195-202. (Pubitemid 43723896)
42. Sugawara T, Zaima N, Yamamoto A, Sakai S, Noguchi R, Hirata T. Isolation of sphingoid bases of sea cucumber cerebrosides and their cytotoxicity against human colon cancer cells. Biosci Biotechnol Biochem 2006;70:2906-12. (Pubitemid 46021548)
43. Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, et al. Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol Cancer Ther 2009;8:1430-7.
44. Oskouian B, Saba J. Sphingosine-1-phosphate metabolism and intestinal tumorigenesis: lipid signaling strikes again. Cell Cycle 2007;6:522-7. (Pubitemid 46440422)
45. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 2009;23:405-14.
46. Shida D, Fang X, Kordula T, Takabe K, Lepine S, Alvarez SE, et al. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 2008;68:6569-77.
47. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90. (Pubitemid 27136715)
48. Davidson LA, Jiang YH, Derr JN, Aukema HM, Lupton JR, Chapkin RS. Protein kinase C isoforms in human and rat colonic mucosa. Arch Biochem Biophys 1994;312:547-53. (Pubitemid 24259111)
49. Ahn EH, Schroeder JJ. Sphinganine causes early activation of JNK and p38 MAPK and inhibition of AKT activation in HT-29 human colon cancer cells. Anticancer Res 2006;26:121-7. (Pubitemid 43206068)
50. King CC, Zenke FT, Dawson PE, Dutil EM, Newton AC, Hemmings BA, et al. Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1. J Biol Chem 2000;275:18108-13. (Pubitemid 30414760)
51. Fyrst H, Oskouian B, Bandhuvula P, Gong Y, Byun HS, Bittman R, et al. Natural sphingadienes inhibit Akt-dependent signaling and prevent intestinal tumorigenesis. Cancer Res 2009;69:9457-64.